-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Jasper Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2019 to Q2 2025.
- Jasper Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2025 was -$26.7M, a 83.2% decline year-over-year.
- Jasper Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2025 was -$90.9M, a 45.6% decline year-over-year.
- Jasper Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$71.3M, a 10.6% decline from 2023.
- Jasper Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$64.5M, a 71.1% decline from 2022.
- Jasper Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$37.7M, a 23% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)